Zymeworks Inc. (ZYME)

NMS – Real Time Price. Currency in USD

23.90

-0.13 (-0.54%)

At close: May 12, 2026, 4:00 PM EDT

Stock details

Previous close: 23.89$
Day's range: 23.39 - 26.21$
52-week range: 10.93 - 29.75$
Volume: 1 454 524
Average volume: 640 397
Beta: 0.19
EPS (TTM): -1.37
PE ratio (TTM): N/A
Forward P/E: 19.36
Market cap: 1 757 681 565
Shares outstanding: 73 573 946
Dividend yield: N/A
Next earnings date: 2026-07-30
Sector: Healthcare
Industry: Biotechnology

About the company

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set o... read more

CEO: Kenneth Galbraith
Country: United States
IPO Date: 2017-04-28
Employees: 264
Fiscal Year End: January - December
Website: https://www.zymeworks.com

Revenue Breakdown

Multifunctional Biotherapeutics / 100.00%

News

No Data

There are no news for this stock.

Chart: ZYME

Loading Chart...

Overall Score

2.7 / 1027%

Financial Strength

5.8

Profitability

Effectiveness

Growth

1.8

Forecast

5.5

Valuation

4.9

Dividend

Economic Moat

Octagon View

Strength & Weakness

Cash reserves $244.3M barely cover the upcoming debt maturities $263.5M

Total current assets $385.7M exceed Total current liabilities $35.6M, highlighting excellent liquidity

Debt-to-equity ratio (1.6) far exceeds the industry average, reflecting over-leverage

Interest coverage ratio (-22.8x) is dangerously low, suggesting debt repayment risks

Negative free cash flow -$45.9M limits the company's ability to reinvest or pay down debt

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	10.82	6.05	10
Quick ratio	10.82	5.63	10
Debt to Equity	1.61	0.30	4.0
Debt to Assets	0.55	1.04	4.0
Interest coverage	-22.81	-16.91	1.0
Weighted average score			5.8

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	412M	76M	76M	106M	81M
Gross Profit	400M	59M	65M	95M	71M
Operating Income	131M	-138M	-120M	-93M	-114M
Net Income	124M	-119M	-123M	-81M	-103M
EBITDA	143M	-121M	-109M	-82M	-104M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	-18.23	-11.73	1.0
Operating margin %	-1956.73	-24.60	1.0
Net margin %	-1833.97	-172.20	1.0
EBITDA margin %	-1838.50	-201.27	1.0
Cash flow margin %	-1898.59	-156.39	1.0
Weighted average score			1.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-18.26	-57.97	1.0
ROE	-26.78	-63.56	1.0
ROIC	-22.25	-42.57	1.0
ROCE	-7.89	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	-46.19	-1005	1.0
Next quarter	497.57	734.48	10
Current year	173.38	214.29	10
Next year	-29.02	-69.96	1.0
Weighted average score			5.5

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-4.24	-7.16	-7.26	-335.43	1.0
Y/Y	-91.11	-95.09	-96.66	-1241.91	1.0
3y average	-14.09	-54.97	-50.45	-37.46	1.0
5y average	274.45	-4.7	-7.78	4.48	4.0
Weighted average score					1.8

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	4.21	-5.25	10
PEG (5yr expected)	N/A	0.27	1.0
P/S	22.16	64.66	5.8
P/B	10.76	2.96	2.8
Weighted average score			4.9

DCF Model

DCF Model PeriodN/A

Discount rateN/A

Perpetual growth rateN/A

Revenue 5 year CAGRN/A

FCF 5 year CAGRN/A

Fair valueN/A

Stock price23.89$

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

$1

UndervaluedStock priceOvervalued

$23.89

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Kenneth Galbraith

Country

United States

IPO Date

2017-04-28

Employees

264

Fiscal Year End

January - December

Website

https://www.zymeworks.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

10.82

6.05

Quick ratio

10.82

5.63

Debt to Equity

1.61

0.30

4.0

Debt to Assets

0.55

1.04

4.0

Interest coverage

-22.81

-16.91

1.0

Weighted average score

5.8

METRIC

2022

2023

2024

2025

TTM

Total Revenue

412M

76M

106M

81M

Gross Profit

400M

59M

65M

95M

71M

Operating Income

131M

-138M

-120M

-93M

-114M

Net Income

124M

-119M

-123M

-81M

-103M

EBITDA

143M

-121M

-109M

-82M

-104M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

-18.23

-11.73

1.0

Operating margin %

-1956.73

-24.60

1.0

Net margin %

-1833.97

-172.20

1.0

EBITDA margin %

-1838.50

-201.27

1.0

Cash flow margin %

-1898.59

-156.39

1.0

Weighted average score

1.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-18.26

-57.97

1.0

ROE

-26.78

-63.56

1.0

ROIC

-22.25

-42.57

1.0

ROCE

-7.89

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

-46.19

-1005

1.0

Next quarter

497.57

734.48

Current year

173.38

214.29

Next year

-29.02

-69.96

1.0

Weighted average score

5.5

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-4.24

-7.16

-7.26

-335.43

1.0

Y/Y

-91.11

-95.09

-96.66

-1241.91

1.0

3y average

-14.09

-54.97

-50.45

-37.46

1.0

5y average

274.45

-4.7

-7.78

4.48

4.0

Weighted average score

1.8

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

4.21

-5.25

PEG (5yr expected)

N/A

0.27

1.0

P/S

22.16

64.66

5.8

P/B

10.76

2.96

2.8

Weighted average score

4.9

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Zymeworks Inc. (ZYME)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Zymeworks Inc. (ZYME)

Stock details

About the company

Revenue Breakdown

News

Chart: ZYME

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$23.89

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: ZYME

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Dividend

Fair Value

$1

$23.89

Economic Moat